Publicação
Equity research of novo Nordisk - a shift in focus: from insulin to GLP-1
| Resumo: | This equity research has the purpose of projecting Novo Nordisk’s operations within the next5 years. There is a growing trend in the company’s focus towards the GLP-1 segment, shifting away from the traditional focus on in sulinglargine. In addition, there is a perception that insulin industry competitors have not suffered a great incidence from the crisis of the pandemic. To evaluate this, we have created a sales-driven financial model for our projections. The end result of as hare price of DKK816.46(10.54% expected return on its current share price)and the sales composition change observed, supports the fore mentioned hypotheses. |
|---|---|
| Autores principais: | Cavalcanti, Eduardo Burguet |
| Assunto: | Valuation Forecasting Health Finance Equity research Health care Insulin Pharmaceutical industry Patents Glp-1 Obesity Pipeline Pharmaceuticals |
| Ano: | 2022 |
| País: | Portugal |
| Tipo de documento: | dissertação de mestrado |
| Tipo de acesso: | acesso aberto |
| Instituição associada: | Universidade Nova de Lisboa |
| Idioma: | inglês |
| Origem: | Repositório Institucional da UNL |
| Resumo: | This equity research has the purpose of projecting Novo Nordisk’s operations within the next5 years. There is a growing trend in the company’s focus towards the GLP-1 segment, shifting away from the traditional focus on in sulinglargine. In addition, there is a perception that insulin industry competitors have not suffered a great incidence from the crisis of the pandemic. To evaluate this, we have created a sales-driven financial model for our projections. The end result of as hare price of DKK816.46(10.54% expected return on its current share price)and the sales composition change observed, supports the fore mentioned hypotheses. |
|---|